0000000000006726

AUTHOR

Godefridus J. Peters

0000-0002-5447-2877

showing 21 related works from this author

Cyclin dependent kinase-1 (Cdk-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (pdac)

2021

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans, due to late diagnosis and limited treatment possibilities. Improved treatment for PDAC patients is warranted. Cyclin-dependent kinase 1 (CDK1) is a stimulator of cell cycle progression and its activity is regularly enhanced in pancreatic cancer cells. Therefore, CDK1 has been proposed as a novel drug target to treat patients with PDAC. This review describes the potential of CDK1 inhibition as a treatment for PDAC by outlining the molecular pathways influenced by CDK1 inhibition and new therapeutic strategies. Abstract The role of CDK1 in PDAC onset and development is two-fold. Firstly, since …

Cancer ResearchCell cycle checkpointendocrine system diseasesmedicine.medical_treatmentReviewenvironment and public healthTargeted therapyCyclin-dependent kinaseCancer stem cellPancreatic cancermedicineNovel treatmentCDK1 inhibitionRC254-282Cyclin-dependent kinase 1biologyChemistryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPDACPancreatic cancerCell cyclemedicine.diseaseenzymes and coenzymes (carbohydrates)Oncologybiology.proteinCancer researchStem cellbiological phenomena cell phenomena and immunityCell cycle regulation
researchProduct

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A co…

2020

Abstract Background Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation. Methods Modulation of glycolytic gene expression was evaluated by PCR arrays in tumour cells and primary cultures growing under hypoxia, in spheroids and after PCFT silencing. Inhibitors of lactate dehydrogenase (LDH-A) were tested in vitro and in vivo. LDH-A expression was determined in tissue microarrays of radically resected malignant pleural mesothelioma (MPM, N = 33) and diffuse peritoneal mesothelioma (DMPM, N = 56) patients. Results Overexpression of hypoxia…

MesotheliomaCancer ResearchPleural NeoplasmsCell Culture TechniquesPemetrexedDeoxycytidineArticle03 medical and health sciencesMice0302 clinical medicinelactate dehydrogenase inhibitorsIn vivoAntigens NeoplasmCell Line TumormedicineGene silencingAnimalsHumansMesotheliomaEnzyme InhibitorsCarbonic Anhydrase IXPeritoneal Neoplasms030304 developmental biology0303 health sciencesL-Lactate DehydrogenaseCell growthChemistryhypoxiaMesothelioma MalignantDrug SynergismHypoxia (medical)Translational researchmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaXenograft Model Antitumor AssaysGemcitabineGemcitabineCell HypoxiaGene Expression Regulation NeoplasticPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPeritoneal mesotheliomaCancer researchFemalemedicine.symptomProton-Coupled Folate Transportermedicine.drugBritish journal of cancer
researchProduct

3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma

2020

A new series of imidazo[2,1-b][1,3,4]thiadiazole derivatives was efficiently synthesized and screened for their in vitro antiproliferative activity on a panel of pancreatic ductal adenocarcinoma (PDAC) cells, including SUIT-2, Capan-1 and Panc-1. Compounds 9c and 9l, showed relevant in vitro antiproliferative activity on all three pre-clinical models with half maximal inhibitory concentration (IC50) ranging from 5.11 to 10.8 &micro

antiproliferative activityPancreatic ductal adenocarcinomaendocrine system diseasespancreatic cancerPharmaceutical ScienceImidazo[21-b][134]thiadiazole derivativeAnalytical Chemistryresistancelcsh:QD241-44103 medical and health sciences0302 clinical medicinelcsh:Organic chemistryPancreatic cancerDrug DiscoverymedicinePhysical and Theoretical ChemistryIC50imidazo[21-<i>b</i>][134]thiadiazole derivatives030304 developmental biologyIndole test0303 health sciencesmigration assayMigration AssayChemistryOrganic ChemistryBiological activityindole compoundsmedicine.diseaseIn vitrodigestive system diseasesIndole compoundChemistry (miscellaneous)Cell culture030220 oncology & carcinogenesisCancer researchMolecular Medicine
researchProduct

Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole …

2019

Heterocyclic rings are recognized as key components of many natural, semi-synthetic and synthetic molecules with a broad spectrum of biological activities. Among these molecules, the indole and imidazo[2,1-b][1,3,4]thiadiazole systems have recently been described as useful scaffolds for the design of anticancer agents. Herein the antitumor activity of a series of 3-(6-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indoles, designed as hybrid structures, was assessed. Seven out of 10 compounds (1a-g) were submitted to National Cancer Institute (NCI). Remarkably, compound 1g showed antiproliferative activity against the full panel of sixty human cancer lines, with half-maximal inhibitory conc…

Cancer Research3Stereochemistry1-b][1Indole systemAntineoplastic Agent03 medical and health sciences0302 clinical medicine4]thiadiazole derivativeCell MovementCell Line TumorPancreatic cancermedicineImidazo[2Cell ProliferationBiological evaluationAntitumor activityIndole testChemistryCancerAnti-migratory activityPancreatic cancerGeneral Medicinemedicine.diseaseIn vitroPancreatic NeoplasmsOncologyIndolePancreatic cancer cell030220 oncology & carcinogenesisAnti-proliferative activityHuman cancerHuman
researchProduct

GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

2021

Pancreatic cancer is an aggressive malignancy with increasing incidence and poor prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer patients present with locally advanced or metastatic disease characterized by inherent resistance to chemotherapy. These features pose a series of therapeutic challenges and new targets are urgently needed. Glycogen synthase kinase 3 beta (GSK3β) is a conserved serine/threonine kinase, which regulates key cellular processes including cell proliferation, DNA repair, cell cycle progression, signaling and metabolic pathways. GSK3β is implicated in non-malignant and malignant diseases including inflammation, neurodegenerative …

Cancer ResearchDNA repairDruggabilityDiseaseMalignancyPancreatic cancerHumansMedicinePharmacology (medical)GSK3BCell ProliferationPharmacologyGlycogen Synthase Kinase 3 betabusiness.industryKinaseGSK3βCancerTumor chromatin profilingOncogenesPancreatic cancermedicine.diseaseAnticancer drug combinationsPancreatic NeoplasmsInfectious DiseasesOncologyDrug Resistance NeoplasmCancer researchbusinessChemoresistanceDrug Resistance Updates
researchProduct

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

2018

Cancer Researchbiologybusiness.industryAfatiniblung cancer EGFR epidermal growth factor receptor inhibition resistancemedicine.diseaseEGFR Tyrosine Kinase InhibitorsGefitinibCancer researchbiology.proteinMedicinePharmacology (medical)OsimertinibEpidermal growth factor receptorErlotinibNon small cellbusinessLung cancermedicine.drug
researchProduct

New Topsentin analogs as inhibitors of biofilm formation

biofilm Topsentin analogs phatogensSettore CHIM/08 - Chimica Farmaceutica
researchProduct

A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells

2021

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal form of cancer characterized by drug resistance, urging new therapeutic strategies. In recent years, protein kinases have emerged as promising pharmacological targets for the treatment of several solid and hematological tumors. Interestingly, cyclin-dependent kinase 1 (CDK1) is overexpressed in PDAC tissues and has been correlated to the aggressive nature of these tumors because of its key role in cell cycle progression and resistance to the induction of apoptosis. For these reasons, CDK1 is one of the main causes of chemoresistance, representing a promising pharmacological target. In this study, we report the synthesis of new 1,2,4…

Indolespancreatic cancerPharmaceutical ScienceAntineoplastic AgentsApoptosisArticleAnalytical ChemistryStructure-Activity RelationshipQD241-441CDK1 inhibitorantiproliferativeCatalytic DomainCell Line TumorDrug DiscoveryCDC2 Protein KinaseHumansPhysical and Theoretical ChemistryProtein Kinase InhibitorsCell ProliferationOxadiazolesOrganic ChemistryImidazoles124-oxadiazolePDACmarine alkaloidMolecular Docking SimulationPancreatic NeoplasmsChemistry (miscellaneous)Molecular Medicinemarine alkaloidstopsentinDrug Screening Assays Antitumor124-oxadiazole; marine alkaloids; topsentin; CDK1 inhibitor; pancreatic cancer; PDAC; antiproliferative; apoptosisCarcinoma Pancreatic DuctalProtein BindingSignal TransductionMolecules
researchProduct

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance.

2021

Aim: Because mutations of splicing factor 3B subunit-1 (SF3B1) have been identified in 4% of pancreatic ductal adenocarcinoma (PDAC) patients, we investigated the activity of new potential inhibitors of SF3B1 in combination with gemcitabine, one of the standard drugs, in PDAC cell lines. Methods: One imidazo[2,1-b][1,3,4]thiadiazole derivative (IS1) and three indole derivatives (IS2, IS3 and IS4), selected by virtual screening from an in-house library, were evaluated by the sulforhodamine-B and wound healing assay for their cytotoxic and antimigratory activity in the PDAC cells SUIT-2, Hs766t and Panc05.04, the latter harbouring the SF3B1 mutations. The effects on the splicing pattern of pr…

DrugPancreatic ductal adenocarcinomaKey genesbusiness.industrymedia_common.quotation_subjectPancreatic ductal adenocarcinoma gemcitabine indole derivatives anti-proliferative activity antimigratory activity SF3B1 RON hENT1Affect (psychology)medicine.diseaseGemcitabineMetastasisPancreatic cancerCancer researchmedicinebusinessmedia_commonmedicine.drugCancer drug resistance (Alhambra, Calif.)
researchProduct

Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells

2020

A new series of eighteen imidazo [2,1-b] [1,3,4]thiadiazole derivatives was efficiently synthesized and screened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. Two out of eighteen derivatives, compounds 12a and 12h, showed remarkably cytotoxic activity with the half maximal inhibitory concentration values (IC50) ranging from 0.23 to 11.4 μM, and 0.29–12.2 μM, respectively. However, two additional compounds, 12b and 13g, displayed remarkable in vitro antiproliferative activity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized (SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), elici…

Inhibition of migrationAntimetabolites AntineoplasticEpithelial-Mesenchymal Transition3Modulation of EMTPTK2VimentinAntineoplastic AgentsApoptosisThiophenesAntiproliferative activity1-b][1DeoxycytidinePancreatic ductal adenocarcinomaThiadiazolesSDG 3 - Good Health and Well-beingCell MovementPancreatic cancerDrug DiscoveryThiadiazolesmedicineTumor Cells CulturedImidazo[21-b][134]thiadiazole derivativesHumansPTK2/FAKIC50Cell ProliferationImidazo[2Pharmacologybiology4]thiadiazole derivativesChemistryOrganic ChemistryDrug SynergismGeneral Medicinemedicine.diseaseGemcitabinePancreatic NeoplasmsCell cultureDrug Resistance NeoplasmImidazo[21-b][134]thiadiazole derivatives Pancreatic ductal adenocarcinoma Antiproliferative activity Inhibition of migration Spheroids shrinkage Modulation of EMT PTK2/FAKbiology.proteinCancer research/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPhosphorylationSpheroids shrinkageTyrosine kinaseCarcinoma Pancreatic DuctalEuropean Journal of Medicinal Chemistry
researchProduct

Autophagy

2012

Klionsky, Daniel J. et al.

autophagy assays[SDV]Life Sciences [q-bio]AutolysosomeAutophagosome maturationautophagosomeBioinformaticsstressChaperone-mediated autophagyModelsLC3MESH: Animalsguidelinesautolysosome autophagosome flux LC3 lysosome phagophore stress vacuoleSettore BIO/06 - Anatomia Comparata E CitologiaComputingMilieux_MISCELLANEOUSSettore BIO/17Autophagy databaseautolysosome3. Good healthddc:540lysosomeEnergy and redox metabolism Mitochondrial medicine [NCMLS 4]methods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIANeuroniMAP1LC3BHumanautophagygenetics [Autophagy]AutofagiaMESH: Autophagy*/genetics[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAutofagia; Neuroni; istologiaBiologyModels BiologicalLC3; autolysosome; autophagosome; flux; lysosome; phagophore; stress; vacuoleddc:570AutophagyAnimalsHumansAutophagy-Related Protein 7[SDV.BC] Life Sciences [q-bio]/Cellular BiologyBiological Assay/methodsMolecular BiologyBiologyAutophagy; guidelines; autophagy assaysistologiaphagophoreMESH: HumansAnimals; Biological Assay; Humans; Models Biological; AutophagyvacuoleAnimal[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH: Models BiologicalPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]Cell BiologyBiologicalAutophagy/geneticsfluxAutophagosome membraneAutophagy Protein 5Human medicineMESH: Biological Assay/methods*Neuroscienceautolysosome; autophagosome; flux; LC3; lysosome; phagophore; stress; vacuoleAutophagy
researchProduct

Synthesis of novel 1,2,4-oxadiazole topsentin analogs with antitumor activity

2019

Synthesis of novel 1,2,4-oxadiazole topsentin analogs with antitumor activity

antitumor activity topsentin analogs oxadiazole
researchProduct

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

2016

Seuls les 100 premiers auteurs dont les auteurs INRA ont été entrés dans la notice. La liste complète des auteurs et de leurs affiliations est accessible sur la publication.; International audience; In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues…

[SDV]Life Sciences [q-bio]autophagosomeReview Articleddc:616.07stressstreLC3MESH: AnimalsSettore MED/49 - Scienze Tecniche Dietetiche ApplicateSettore BIO/06 - Anatomia Comparata E Citologiachaperone-mediated autophagyComputingMilieux_MISCELLANEOUSSettore BIO/11Pharmacology. TherapySettore BIO/13standards [Biological Assay]autolysosomeMESH: Autophagy*/physiologylysosomemethods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIAErratumHumanBiochemistry & Molecular BiologySettore BIO/06physiology [Autophagy]Chaperonemediated autophagy[SDV.BC]Life Sciences [q-bio]/Cellular BiologyNOautophagy guidelines molecular biology ultrastructureautolysosome; autophagosome; chaperone-mediated autophagy; flux; LC3; lysosome; macroautophagy; phagophore; stress; vacuoleMESH: Biological Assay/methodsMESH: Computer Simulationddc:570Autolysosome Autophagosome Chaperonemediated autophagy Flux LC3 Lysosome Macroautophagy Phagophore Stress VacuoleAutophagyAnimalsHumansComputer SimulationSettore BIO/10ddc:612BiologyphagophoreMESH: HumansvacuoleAnimalLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole; Animals; Biological Assay; Computer Simulation; Humans; Autophagy0601 Biochemistry And Cell BiologyfluxmacroautophagyMESH: Biological Assay/standards*Human medicineLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole
researchProduct

Biological evaluation of new 1,2,4-oxadiazole topsentin analogs as anticancer agents

2019

anticancer agents topsentin topsentin analogs novel targetsSettore CHIM/08 - Chimica Farmaceutica
researchProduct

New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modu…

2020

Background/aim A new class of imidazo[2,1-b][1,3,4]thiadiazole compounds have recently been evaluated as inhibitors of phosphorylation of focal adhesion kinase (FAK) in pancreatic cancer. FAK is overexpressed in mesothelioma and has recently emerged as an interesting target for the treatment of this disease. Materials and methods Ten imidazo[2,1-b][1,3,4]thiadiazole compounds characterized by indole bicycle and a thiophene ring, were evaluated for their cytotoxic activity in two primary cell cultures of peritoneal mesothelioma, MesoII and STO cells. Results Compounds 1a and 1b showed promising antitumor activity with IC50 values in the range of 0.59 to 2.81 μM in both cell lines growing as …

MesotheliomaCancer ResearchFAKbiologyChemistrygemcitabineSettore BIO/05 - Zoologiaimidazo[21-b][134]thiadiazole compoundGeneral MedicineEquilibrative nucleoside transporter 1medicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineFocal adhesionOncologyCell culturePancreatic cancerbiology.proteinmedicineCancer researchPhosphorylationCytotoxic T cellhuman equilibrative nucleoside transporter-1.Nucleosidemedicine.drugAnticancer Research
researchProduct

Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma

2021

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers because of diagnosis at late stage and inherent/acquired chemoresistance. Recent advances in genomic profiling and biology of this disease have not yet been translated to a relevant improvement in terms of disease management and patient’s survival. However, new possibilities for treatment may emerge from studies on key epigenetic factors. Deregulation of microRNA (miRNA) dependent gene expression and mRNA splicing are epigenetic processes that modulate the protein repertoire at the transcriptional level. These processes affect all aspects of PDAC pathogenesis and have great potential to unravel new therapeutic targets…

0301 basic medicineCancer Researchsplicing deregulationinteractionDiseaseBiologymedicine.disease_causeinteraction; miRNA; PDAC; splicing deregulation; splicing modulation03 medical and health sciencesSplicing factor0302 clinical medicineDownregulation and upregulationCell Line TumormicroRNAGene expressionmedicineHumansEpigeneticsMolecular BiologymiRNAPDACDNA MethylationGene Expression Regulation NeoplasticPancreatic NeoplasmsRepressor ProteinsMicroRNAs030104 developmental biology030220 oncology & carcinogenesisRNA splicingCancer researchKRASRNA Splicing Factorssplicing modulationCarcinoma Pancreatic Ductal
researchProduct

“Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity…

2020

Simple Summary Despite the enormous advance in biomarker discovery, many potential biomarkers of drug activity are unable to satisfy the clinical need due to inadequate sensitivity and specificity. The nucleoside transporter hENT-1 has been studied as a potential biomarker to predict the effect of the widely used anticancer drug gemcitabine in pancreatic cancer. However, several studies showed controversial results regarding the predictive value of hENT-1, prompting new analyses with larger cohorts of patients and standardized methodologies. Improved insights on molecular mechanisms underlying hENT-1 expression and activity should also help in the identification of subsets of patients who a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFOLFIRINOXpancreatic cancerSettore BIO/05 - Zoologiaclinical outcomeDUCTAL ADENOCARCINOMAEquilibrative nucleoside transporter 1lcsh:RC254-282Articlehuman equilibrative nucleoside transporter 103 medical and health sciences0302 clinical medicinePancreatic cancerInternal medicinemedicine1112 Oncology and CarcinogenesisScience & Technologydrug resistanceROLESNucleoside analoguebiology1 HENT1business.industryCombination chemotherapyCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineRegimenLEVELS PREDICT RESPONSE030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSMETASTASISbiology.proteinSURVIVALBiomarker (medicine)ADJUVANT GEMCITABINEbusinessLife Sciences & BiomedicineRESISTANCEmedicine.drug
researchProduct

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

2018

0301 basic medicineMesotheliomaLung NeoplasmsPleural NeoplasmsPemetrexed03 medical and health sciences0302 clinical medicineGeneticsmedicineBiomarkers TumorHumansMesotheliomaProton-coupled folate transporterPharmacologybusiness.industryPleural mesotheliomaMesothelioma Malignantmedicine.diseasechemoresistance mesothelioma PCFT pemetrexed030104 developmental biologyPemetrexedDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchMolecular MedicineBiomarker (medicine)businessProton-Coupled Folate Transportermedicine.drugPharmacogenomics
researchProduct

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

2017

Background There is increasing evidence of a constitutive activation of Akt in pancreatic ductal adenocarcinoma (PDAC), associated with poor prognosis and chemoresistance. Therefore, we evaluated the expression of phospho-Akt in PDAC tissues and cells, and investigated molecular mechanisms influencing the therapeutic potential of Akt inhibition in combination with gemcitabine. Methods Phospho-Akt expression was evaluated by immunohistochemistry in tissue microarrays (TMAs) with specimens tissue from radically-resected patients (n = 100). Data were analyzed by Fisher and log-rank test. In vitro studies were performed in 14 PDAC cells, including seven primary cultures, characterized for their…

0301 basic medicineOncologyMaleCancer ResearchBiopsyAKT1ApoptosisAkt; Gemcitabine; Pancreatic ductal adenocarcinoma; Synergism; Hematology; Molecular Biology; Oncology; Cancer ResearchDeoxycytidinePancreatic ductal adenocarcinoma0302 clinical medicineCell MovementTumor Cells CulturedGlucose Transporter Type 1medicine.diagnostic_testChemistryCell CyclePancreatic NeoplasmDrug Synergismlcsh:Diseases of the blood and blood-forming organsHematologyCell cycleMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisOncologyAkt; Gemcitabine; Pancreatic ductal adenocarcinoma; Synergism; Aged; Apoptosis; Biopsy; Carcinoma Pancreatic Ductal; Cell Cycle; Cell Movement; Deoxycytidine; Drug Synergism; Female; Glucose Transporter Type 1; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphoproteins; Prognosis; Proto-Oncogene Proteins c-akt; RNA Messenger; Spheroids Cellular; Tumor Cells Cultured; Hematology; Molecular Biology; Oncology; Cancer Research030220 oncology & carcinogenesisPhosphoproteinFemalemedicine.drugHumanCarcinoma Pancreatic Ductalmedicine.medical_specialtyPrognosilcsh:RC254-282Flow cytometry03 medical and health sciencesInternal medicinePancreatic cancerSpheroids CellularmedicineHumansRNA MessengerProtein kinase BMolecular BiologyPI3K/AKT/mTOR pathwayAgedlcsh:RC633-647.5ResearchAktSynergismApoptosimedicine.diseasePhosphoproteinsGemcitabineGemcitabinePancreatic Neoplasms030104 developmental biologyCancer cellCancer researchProto-Oncogene Proteins c-akt
researchProduct

Erratum

2016

Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; Arozena, AA; Adachi, H; Adams, CM; Adams, PD; Adeli, K; Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghiso, J; Airoldi, EM; Ait-Si-Ali, S; Akematsu, T; Akporiaye, ET; Al-Rubeai, M; Albaiceta, GM; Albanese, C; Albani, D; Albert, ML; Aldudo, J; Algul, H; Alirezaei, M; Alloza, I; Almasan, A; Almonte-Beceril, M; Alnemri, ES; Alonso, C; Altan-Bonnet, N; Altieri, DC; Alvarez, S; Alvarez-Erviti, L; Alves, S; Amadoro, G; Amano, A; Amantini, C; Ambrosio, S; Amelio, I; Amer, AO; Amessou, M; Amon, A; An, Z; Anania, FA; Andersen, SU; Andley, UP; Andreadi, CK; Andrieu-Ab…

0301 basic medicineSettore BIO/06biologyCell Biology[SDV.BC]Life Sciences [q-bio]/Cellular Biologybiology.organism_classificationCell biologyInterpretation (model theory)03 medical and health sciencesArama030104 developmental biologyMolecular BiologyHumanitiesComputingMilieux_MISCELLANEOUS
researchProduct

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung can…

2021

Cancer Researchmedicine.medical_specialtyLung Neoplasmsprotein p37monoclonal antibody pd4medicine.disease_causeMycoplasmaSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansOsimertinibLung cancercytidine deaminaseEGFR inhibitorsAcrylamidesAniline CompoundsHematologybusiness.industrygemcitabineGeneral MedicineMycoplasmaCytidine deaminasemedicine.diseaseErbB ReceptorsOncologymonoclonal antibodyosimertinibCancer research/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingbusiness
researchProduct